

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 7, 2025

lentiCRISPR v2

RRID:Addgene_52961

Type: Plasmid

Proper Citation

RRID:Addgene_52961

Plasmid Information

URL: <http://www.addgene.org/52961>

Proper Citation: RRID:Addgene_52961

Insert Name: Cas9

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:25075903](https://pubmed.ncbi.nlm.nih.gov/25075903/)

Vector Backbone Description: Backbone Size:10000; Vector Backbone:Custom; Vector Types:Mammalian Expression, Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Comments: This plasmid is an updated version of the original lentiCRISPR (Addgene plasmid #49535) IMPORTANT: The primers suggestions listed above are for gene inserts that exist in the untouched vector. After you have inserted your gRNA, you should use hU6-F (5'-GAGGGCCTATTTCCCATGATT-3') or LKO.1 5'(5'- GACTATCATATGCTTACCGT-3') to sequence that region. Special note from the Zhang lab: We are constantly improving our CRISPR reagents. Please check <https://zlab.bio/> for the most up-to-date information.

Plasmid Name: lentiCRISPR v2

Record Creation Time: 20220422T222310+0000

Record Last Update: 20231115T080821+0000

Ratings and Alerts

No rating or validation information has been found for lentiCRISPR v2.

No alerts have been found for lentiCRISPR v2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 960 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Fu W, et al. (2025) Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. *Cell research*, 35(1), 23.

Wang M, et al. (2025) Gut microbiota protect against colorectal tumorigenesis through lncRNA Snhg9. *Developmental cell*.

Wolf G, et al. (2025) The efflux pump ABCC1/MRP1 constitutively restricts PROTAC sensitivity in cancer cells. *Cell chemical biology*, 32(2), 291.

Hosono Y, et al. (2025) Identification of β -galactosylceramide as an endogenous mammalian antigen for iNKT cells. *The Journal of experimental medicine*, 222(2).

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell*, 187(2), 390.

Li F, et al. (2024) Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer. *Nature cancer*, 5(1), 131.

Wang HH, et al. (2024) Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are associated with neurodevelopmental disorders. *The Journal of clinical investigation*, 134(2).

Weis D, et al. (2024) Biallelic Cys141Tyr variant of SEL1L is associated with neurodevelopmental disorders, agammaglobulinemia, and premature death. *The Journal of clinical investigation*, 134(2).

Cevatemre B, et al. (2024) Exploiting epigenetic targets to overcome taxane resistance in prostate cancer. *Cell death & disease*, 15(2), 132.

Guo P, et al. (2024) A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis. *eLife*, 13.

Lv S, et al. (2024) TFE3-SLC36A1 axis promotes resistance to glucose starvation in kidney

cancer cells. *The Journal of biological chemistry*, 300(5), 107270.

Zhang Y, et al. (2024) ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers. *Nature communications*, 15(1), 4883.

Sepulveda GP, et al. (2024) DOT1L stimulates MYC/Mondo transcription factor activity by promoting its degradation cycle on chromatin. *bioRxiv : the preprint server for biology*.

Pahl MC, et al. (2024) Variant to gene mapping for carpal tunnel syndrome risk loci implicates skeletal muscle regulatory elements. *EBioMedicine*, 101, 105038.

Hazan JM, et al. (2024) Integration of transcription regulation and functional genomic data reveals lncRNA SNHG6's role in hematopoietic differentiation and leukemia. *Journal of biomedical science*, 31(1), 27.

Jiang F, et al. (2024) A landscape of gene expression regulation for synovium in arthritis. *Nature communications*, 15(1), 1409.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. *Cancer cell*.

Deng B, et al. (2024) AURKA emerges as a vulnerable target for KEAP1-deficient non-small cell lung cancer by activation of asparagine synthesis. *Cell death & disease*, 15(3), 233.

Wang L, et al. (2024) Induction of immortal-like and functional CAR T cells by defined factors. *The Journal of experimental medicine*, 221(5).

Kundu A, et al. (2024) l-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models. *The Journal of clinical investigation*, 134(13).